- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05671185
rTMS for Depressive, Positive and Negative Symptoms, and Physiological Indices of Schizophrenia Patients
Therapeutic Effect of Repetitive Transcranial Magnetic Stimulation for Depressive, Positive and Negative Symptoms, and Physiological Indices of Schizophrenia Patients
Around 40% of schizophrenia patients present depressive symptoms, which are associated with elevated suicide and violence risk and poor prognosis and quality of life. Recent meta-analysis showed the effect size of antidepressants for depressive symptoms of schizophrenia patients was as low as 0.25, so new therapeutic approach is warranted.
Repetitive transcranial magnetic stimulation (rTMS) is a non-invasive, anesthesia-free brain stimulation therapy for treatment refractory depression. Currently, rTMS is classified as high-frequency stimulation (>5Hz, usually 10Hz or 20Hz) and low-frequency inhibition (usually 1Hz). Intermittent theta burst stimulation (iTBS) is a new variant of rTMS, with stimulation frequency as high as 50Hz. Compared with high-frequency rTMS, iTBS has similar therapeutic effect and shorter stimulation duration. Up to now, studies exploring treatment effect of rTMS or iTBS for schizophrenia patients mainly focused on negative symptoms rather than depressive symptoms. Therefore, this study aims to explore treatment effect of rTMS or iTBS of depressive symptoms, negative symptoms, cognitive function and physiological indices for schizophrenia patients.
Study Overview
Status
Conditions
Intervention / Treatment
Study Type
Enrollment (Anticipated)
Phase
- Not Applicable
Contacts and Locations
Study Contact
- Name: Chia-Hao Ma, MD
- Phone Number: 7107 +886-5-5323911
- Email: chiahaoma.tw@gmail.com
Study Locations
-
-
-
Douliu, Yunlin, Taiwan, 640
- Recruiting
- Department of Psychiatry, National Taiwan University Hospital Yunlin Branch
-
Contact:
- Chia-Hao Ma, MD
- Phone Number: 7107 +886-5-532-3911
- Email: chiahaoma.tw@gmail.com
-
Principal Investigator:
- Chia-Hao Ma, MD
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Age ≥ 20 years
- Able to give informed consent
- Diagnosed with schizophrenia or schizoaffective disorder according to DSM-5
- Has a score ≥ 7 on Calgary depression scale for schizophrenia
- The principal psychotropic agents are not changed within one month of the first session of rTMS
Exclusion Criteria:
- DSM-5 defined substance use disorder (excluding tobacco) in the past 3 months
- Have clinically relevant cognitive impairment (e.g., delirium, intellectual disability or MMSE < 15)
- With electronic and/or magnetic implants (e.g. pacemaker, implantable cardioverter defibrillator [ICD], cerebral shunts, cochlear implant, etc.)
- With metallic or mechanic fragments (e.g., screws, plates, stents, clips, etc.)
- Pregnant, or has a pregnancy plan within 3 months
- With any known or history of neurological conditions including cerebral vascular accidents, epilepsy (or epileptiform waves detected by EEG prior to the first session of rTMS), brain tumor or space occupying lesion
- Received rTMS or iTBS treatment within 3 months
- Has a clinically significant abnormality on the screening examination that might affect safety, study participation, or confound interpretation of study results
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Double
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: conventional rTMS
target: left DLPFC protocol: 10Hz for 4 seconds, 120% motor threshold, 75 trains with 26-second interval, 3000 pulses per session, one session per day, five sessions per week, two weeks in total |
rTMS using Magstim TMS system is delivered at the left dorsolateral prefrontal cortex
|
Experimental: iTBS
target: left DLPFC protocol: 3 pulses at 50Hz, 90% motor threshold, repeated at 5Hz, 60 trains of 10 bursts with 8-second intervals, 1800 pulses per session, one session per day, five sessions per week, two weeks in total |
rTMS using Magstim TMS system is delivered at the left dorsolateral prefrontal cortex
|
Sham Comparator: sham rTMS
target: left DLPFC sham probe, the same protocol as active conventional rTMS |
rTMS using Magstim TMS system is delivered at the left dorsolateral prefrontal cortex
|
Sham Comparator: sham iTBS
target: left DLPFC sham probe, the same protocol as active iTBS |
rTMS using Magstim TMS system is delivered at the left dorsolateral prefrontal cortex
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Change from Baseline in Calgary Depression Scale for Schizophrenia
Time Frame: baseline (Day 1), Day 8, Day 15, Day 29, Day 57, Day 85
|
A 9-item scale developed for detecting major depressive episode for schizophrenia patients.
Total score ranges from 0 to 27.
Lower score indicates less depressive symptoms.
A cut-off of 7 points yields to sensitivity of 85% and specificity of 82%.
|
baseline (Day 1), Day 8, Day 15, Day 29, Day 57, Day 85
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Change from Baseline in Positive and Negative syndrome scale
Time Frame: baseline (Day 1), Day 8, Day 15, Day 29, Day 57, Day 85
|
A 30-item scale developed to evaluating positive, negative and general symptoms for schizophrenia patients.
Total score ranges from 30 to 210.
Lower score indicates fewer schizophrenic symptoms.
|
baseline (Day 1), Day 8, Day 15, Day 29, Day 57, Day 85
|
Change from Baseline in Negative symptoms assessment 16
Time Frame: baseline (Day 1), Day 8, Day 15, Day 29, Day 57, Day 85
|
A scale developed to evaluating negative symptoms for schizophrenia patients.
Items are scored based on behaviors during the interview (items 1-4, 6, 7, 9, 11, 15, 16) or previous 7 days (items 5, 8, 10, 12-14) on a 6-point scale from 1 to 6.
The NSA-16 domain scores are the sum of item scores in each domain i.e. communication (min score 4, max score 24), emotion/affect (min 3, max 18), social involvement (min 3, max 18), motivation (min 4, max 24), and retardation (min 2, max 12); with higher scores denoting more severe negative symptoms in schizophrenia.
|
baseline (Day 1), Day 8, Day 15, Day 29, Day 57, Day 85
|
Change from Baseline in Clinical global impression
Time Frame: baseline (Day 1), Day 8, Day 15, Day 29, Day 57, Day 85
|
A scale for primary-care psychiatrist to evaluate global symptom severity of a patient in comparison with others with same diagnosis.
Lower score indicates less severe illness.
|
baseline (Day 1), Day 8, Day 15, Day 29, Day 57, Day 85
|
Change from Baseline in Self-Reported Graphic version of the Personal and Social Performance Scale
Time Frame: baseline (Day 1), Day 8, Day 15, Day 29, Day 57, Day 85
|
A 22-item self-rated scale for schizophrenia patients, which includes four domains, i.e., global function (6 items, total scores 6-18), personal and social performance (5 items, total scores 5-15), self-care (6 items, total scores 6-18) and disturbing behaviors (5 items, total scores 5-15).
Lower score indicates less severe illness.
|
baseline (Day 1), Day 8, Day 15, Day 29, Day 57, Day 85
|
Other Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Change from Baseline in Physiological Parameters - Heart Rate Variability
Time Frame: baseline (Day 1), Day 8, Day 15, Day 29, Day 57, Day 85
|
Measurement of parasympathetic activity.
|
baseline (Day 1), Day 8, Day 15, Day 29, Day 57, Day 85
|
Change from Baseline in Physiological Parameters - Skin Conductance
Time Frame: baseline (Day 1), Day 8, Day 15, Day 29, Day 57, Day 85
|
Measurement of sympathetic activity.
|
baseline (Day 1), Day 8, Day 15, Day 29, Day 57, Day 85
|
Change from Baseline in Physiological Parameters - Body Temperature
Time Frame: baseline (Day 1), Day 8, Day 15, Day 29, Day 57, Day 85
|
Measurement of autonomic nervous system.
|
baseline (Day 1), Day 8, Day 15, Day 29, Day 57, Day 85
|
Change from Baseline in Physiological Parameters - Respiratory Rate
Time Frame: baseline (Day 1), Day 8, Day 15, Day 29, Day 57, Day 85
|
Measurement of autonomic nervous system.
|
baseline (Day 1), Day 8, Day 15, Day 29, Day 57, Day 85
|
Collaborators and Investigators
Investigators
- Principal Investigator: Chia-Hao Ma, MD, Department of Psychiatry, National Taiwan University Hospital Yunlin Branch
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Anticipated)
Study Completion (Anticipated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- 202210011DINC
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Schizophrenia and Related Disorders
-
Northwell HealthWinterlight LabsCompletedSchizophrenia and Related DisordersUnited States
-
Haukeland University HospitalRecruitingBipolar Disorder | Schizophrenia and Related DisordersNorway
-
University of Maryland, BaltimoreRecruiting
-
Vanderbilt University Medical CenterCompletedSchizophrenia and Related DisordersUnited States
-
Örebro University, SwedenActive, not recruitingSchizophrenia and Related DisordersSweden
-
Fundación Pública Andaluza para la gestión de la...Completed
-
University of BernCompletedSchizophrenia and Related DisordersSwitzerland
-
Weill Medical College of Cornell UniversityUniversity of Catania; University of Stirling; Hunter College of The City University...CompletedSchizophrenia and Related DisordersUnited States
-
University of BernTerminatedSchizophrenia and Related DisordersSwitzerland
-
Icahn School of Medicine at Mount SinaiNational Institute of Mental Health (NIMH); Columbia University; Stanford University and other collaboratorsCompleted
Clinical Trials on Repetitive Transcranial Magnetic Stimulation
-
State University of New York - Upstate Medical...RecruitingHeadache | Brain Concussion | Mild Traumatic Brain Injury | Post-Concussion SymptomsUnited States
-
Xuzhou Central HospitalThe Affiliated Hospital of Xuzhou Medical UniversityNot yet recruitingFunctional Magnetic Resonance Imaging | Executive Function Disorder
-
Al-Azhar UniversityCompleted
-
Guangzhou Psychiatric HospitalCompletedCognitive Impairment | Bipolar Disorder | RelapseChina
-
Fatih Sultan Mehmet Training and Research HospitalCompletedFailed Back Surgery Syndrome
-
Veterans Medical Research FoundationUnited States Department of DefenseCompletedHeadache | Gulf War SyndromeUnited States
-
Yi YangRecruitingTranscranial Magnetic StimulationChina
-
Yi YangRecruitingTranscranial Magnetic StimulationChina
-
First Affiliated Hospital of Zhejiang UniversityCompletedBipolar DisorderChina
-
Izmir Katip Celebi UniversityCompletedPost-stroke Shoulder PainTurkey